[go: up one dir, main page]

EA200200316A1 - Соединения для лечения ишемии - Google Patents

Соединения для лечения ишемии

Info

Publication number
EA200200316A1
EA200200316A1 EA200200316A EA200200316A EA200200316A1 EA 200200316 A1 EA200200316 A1 EA 200200316A1 EA 200200316 A EA200200316 A EA 200200316A EA 200200316 A EA200200316 A EA 200200316A EA 200200316 A1 EA200200316 A1 EA 200200316A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
ischemia
connections
treatment
amogut
Prior art date
Application number
EA200200316A
Other languages
English (en)
Other versions
EA005422B1 (ru
Inventor
Хироко Масамуне
Майкл Пол Денинно
Роберт Вилльям Скотт
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200316A1 publication Critical patent/EA200200316A1/ru
Publication of EA005422B1 publication Critical patent/EA005422B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Агонисты А, способы применения таких агонистов Аи фармацевтические композиции, содержащие такие агонисты А. Агонисты Амогут использоваться для уменьшения поражения ткани, возникающего в результате ишемии или гипоксии ткани.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200316A 1999-09-30 2000-09-22 Соединения для лечения ишемии EA005422B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (2)

Publication Number Publication Date
EA200200316A1 true EA200200316A1 (ru) 2002-08-29
EA005422B1 EA005422B1 (ru) 2005-02-24

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200316A EA005422B1 (ru) 1999-09-30 2000-09-22 Соединения для лечения ишемии

Country Status (41)

Country Link
EP (1) EP1216257B1 (ru)
JP (1) JP2003510331A (ru)
KR (1) KR100481605B1 (ru)
CN (1) CN1374967A (ru)
AP (1) AP2002002458A0 (ru)
AR (1) AR029887A1 (ru)
AT (1) ATE312117T1 (ru)
AU (1) AU778185B2 (ru)
BG (1) BG106636A (ru)
BR (1) BR0014384A (ru)
CA (1) CA2386079A1 (ru)
CO (1) CO5180581A1 (ru)
CR (1) CR6592A (ru)
CZ (1) CZ20021020A3 (ru)
DE (1) DE60024649D1 (ru)
EA (1) EA005422B1 (ru)
EC (1) ECSP003682A (ru)
EE (1) EE200200172A (ru)
GE (1) GEP20043241B (ru)
GT (1) GT200000161A (ru)
HK (1) HK1049011A1 (ru)
HR (1) HRP20020253A2 (ru)
HU (1) HUP0202807A3 (ru)
IL (1) IL148222A0 (ru)
IS (1) IS6286A (ru)
MA (1) MA26822A1 (ru)
MX (1) MXPA02003308A (ru)
MY (1) MY133996A (ru)
NO (1) NO20021474L (ru)
NZ (1) NZ517177A (ru)
OA (1) OA12021A (ru)
PA (1) PA8503301A1 (ru)
PE (1) PE20010696A1 (ru)
PL (1) PL357371A1 (ru)
SK (1) SK4182002A3 (ru)
TN (1) TNSN00191A1 (ru)
TR (1) TR200200843T2 (ru)
UA (1) UA73525C2 (ru)
WO (1) WO2001023399A1 (ru)
YU (1) YU23102A (ru)
ZA (1) ZA200202461B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691951C2 (ru) * 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
HRP20040385A2 (en) * 2001-11-02 2005-06-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising an adenosine a<sub>1</sub>/a<sub>2</sub> agonist and a sodium hydrogen exchanger inhibitor
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
EP1687268A1 (en) * 2003-11-10 2006-08-09 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2560843A1 (en) 2004-03-24 2005-10-06 Fasgen, Llc Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
NZ551077A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PL1778239T3 (pl) * 2004-07-28 2014-01-31 Can Fite Biopharma Ltd Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
US20080221203A1 (en) * 2004-08-09 2008-09-11 University Catholique De Louvain Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
KR101197674B1 (ko) * 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. １１-베타 하이드록시스테로이드 탈수소효소 저해제로서의 ｎ-2 아다만타닐-２-페녹시-아세트아미드 유도체
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
CN101039908B (zh) 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
IN2012DN01453A (ru) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
WO2019232403A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (ru) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691951C2 (ru) * 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы

Also Published As

Publication number Publication date
TNSN00191A1 (fr) 2005-11-10
KR20020034206A (ko) 2002-05-08
PL357371A1 (en) 2004-07-26
ZA200202461B (en) 2003-05-28
CZ20021020A3 (cs) 2003-04-16
OA12021A (en) 2006-04-19
CN1374967A (zh) 2002-10-16
IL148222A0 (en) 2002-09-12
EE200200172A (et) 2003-06-16
CO5180581A1 (es) 2002-07-30
CR6592A (es) 2004-02-23
NO20021474L (no) 2002-05-22
HUP0202807A3 (en) 2005-02-28
ECSP003682A (es) 2002-04-23
DE60024649D1 (de) 2006-01-12
BG106636A (bg) 2003-01-31
BR0014384A (pt) 2002-07-02
GT200000161A (es) 2002-03-22
WO2001023399A1 (en) 2001-04-05
MXPA02003308A (es) 2002-10-04
HK1049011A1 (zh) 2003-04-25
YU23102A (sh) 2006-01-16
SK4182002A3 (en) 2003-04-01
AP2002002458A0 (en) 2002-06-30
KR100481605B1 (ko) 2005-04-08
IS6286A (is) 2002-02-26
HUP0202807A2 (hu) 2002-12-28
UA73525C2 (en) 2005-08-15
ATE312117T1 (de) 2005-12-15
AR029887A1 (es) 2003-07-23
EA005422B1 (ru) 2005-02-24
EP1216257B1 (en) 2005-12-07
EP1216257A1 (en) 2002-06-26
PA8503301A1 (es) 2003-06-30
CA2386079A1 (en) 2001-04-05
HRP20020253A2 (en) 2004-04-30
MY133996A (en) 2007-11-30
NO20021474D0 (no) 2002-03-25
NZ517177A (en) 2003-10-31
MA26822A1 (fr) 2004-12-20
PE20010696A1 (es) 2001-07-05
AU778185B2 (en) 2004-11-18
AU7035200A (en) 2001-04-30
GEP20043241B (en) 2004-05-25
TR200200843T2 (tr) 2002-07-22
JP2003510331A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
EA200200316A1 (ru) Соединения для лечения ишемии
EA200000789A1 (ru) N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
EA200300065A1 (ru) Окисленные сложные эфиры 4-йодфениламинобензгидроксамовых кислот
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
BR0200782A (pt) Compostos para o tratamento da isquemia
PT1109812E (pt) Pirrolobenzodiazepinas
EA199800559A1 (ru) Антагонисты гонадотропин-высвобождающего фактора
EA199800564A1 (ru) Антагонисты гонадотропин-высвобождающего фактора
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EE03869B1 (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
NO952151L (no) Injiserbare, taxanderivat-baserte preparater
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
EA200101232A1 (ru) Соединения феноксипропиламина
EE02962B1 (et) Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
EA200200545A1 (ru) Онколитические комбинации для лечения рака
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
EA200100852A1 (ru) Производные резорцина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU